Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients.

Guzmán-Fulgencio M, Jiménez JL, Berenguer J, Fernández-Rodríguez A, López JC, Cosín J, Miralles P, Micheloud D, Muñoz-Fernández MÁ, Resino S.

J Antimicrob Chemother. 2012 May;67(5):1238-45. doi: 10.1093/jac/dkr595.

2.

Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.

Soriano V, Núñez M, Camino N, Maida I, Barreiro P, Romero M, Martin-Carbonero L, Garcia-Samaniego J, González-Lahoz J.

Antivir Ther. 2004 Aug;9(4):505-9.

PMID:
15456081
3.

Association between plasma levels of eotaxin (CCL-11) and treatment response to interferon-alpha and ribavirin in HIV/HCV co-infected patients.

Vargas A, Berenguer J, Catalán P, Miralles P, López JC, Cosín J, Resino S.

J Antimicrob Chemother. 2010 Feb;65(2):303-6. doi: 10.1093/jac/dkp454.

4.

A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients.

Neukam K, Almeida C, Caruz A, Rivero-Juárez A, Rallón NI, Di Lello FA, Herrero R, Camacho A, Benito JM, Macías J, Rivero A, Soriano V, Pineda JA.

J Antimicrob Chemother. 2013 Apr;68(4):915-21. doi: 10.1093/jac/dks488.

5.

Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.

Zylberberg H, Benhamou Y, Lagneaux JL, Landau A, Chaix ML, Fontaine H, Bochet M, Poynard T, Katlama C, Pialoux G, Bréchot C, Pol S.

Gut. 2000 Nov;47(5):694-7.

6.

Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.

Chuang WL, Dai CY, Chang WY, Lee LP, Lin ZY, Chen SC, Hsieh MY, Wang LY, Yu ML.

Antivir Ther. 2005;10(1):125-33.

PMID:
15751770
7.

Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus.

Berenguer J, von Wichmann MA, Quereda C, Miralles P, Mallolas J, López-Aldeguer J, Alvarez-Pellicer J, De Miguel J, Crespo M, Guardiola JM, Tellez MJ, Galindo MJ, Arponen S, Barquilla E, Bellón JM, González-García J; GESIDA 36/03 and 50/06 Study Groups..

J Antimicrob Chemother. 2011 Dec;66(12):2843-9. doi: 10.1093/jac/dkr362.

8.
9.

Dual role of IL-12 in the therapeutic efficacy or failure during combined PEG-Interferon-α2A and ribavirin therapy in patients with chronic hepatitis C.

Araújo AR, Peruhype-Magalhães V, Coelho-dos-Reis JG, Chaves LP, de Lima TA, Pimentel JP, de Paula L, de Almeida CM, Tarragô AM, Tateno A, Levi JE, Teixeira-Carvalho A, Martins-Filho OA, Lira Eda F, Torres KL, Talhari S, Malheiro A.

Immunol Lett. 2013 Jul-Aug;154(1-2):61-9. doi: 10.1016/j.imlet.2013.07.010.

PMID:
23973662
10.

Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.

Yu ML, Chuang WL, Dai CY, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Tsai SL, Kuo HT.

Transl Res. 2006 Sep;148(3):120-7.

PMID:
16938649
11.

PPARγ2 Pro12Ala polymorphism is associated with sustained virological response in HIV/HCV-coinfected patients under HCV therapy.

Fernández-Rodríguez A, Berenguer J, Rallón N, Jiménez-Sousa MA, López JC, Soriano V, García-Álvarez M, Cosín J, Martínez P, Guzmán-Fulgencio M, Miralles P, Miguel Benito J, Resino S.

J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):113-9. doi: 10.1097/QAI.0000000000000282.

PMID:
25072612
12.

Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.

Zografos TA, Liaskos C, Rigopoulou EI, Togousidis E, Makaritsis K, Germenis A, Dalekos GN.

Am J Gastroenterol. 2008 Mar;103(3):605-14. doi: 10.1111/j.1572-0241.2007.01729.x.

PMID:
18190648
13.
14.

[Interferon-alpha and ribavirin combination therapy for co-infection of hepatitis C virus and human immunodeficiency virus].

Zheng YH, He Y, Yang X, Gong GZ, Zhou HY, Zhang CY, Zhou W, Huang L, Ding PP, Li H.

Zhonghua Gan Zang Bing Za Zhi. 2005 Oct;13(10):741-4. Chinese.

PMID:
16248945
15.

Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients.

Kanto T, Inoue M, Oze T, Miyazaki M, Sakakibara M, Kakita N, Matsubara T, Higashitani K, Hagiwara H, Iio S, Katayama K, Mita E, Kasahara A, Hiramatsu N, Takehara T, Hayashi N.

J Gastroenterol. 2012 Feb;47(2):169-78. doi: 10.1007/s00535-011-0466-y.

PMID:
21947705
16.

Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients.

Barreiro P, Labarga P, Martín-Carbonero L, Amor A, Ruiz-Sancho A, Castellares C, González-Lahoz J, Soriano V.

Antivir Ther. 2006;11(7):869-77.

PMID:
17302249
17.

Short Communication: CXCL12 rs1029153 Polymorphism Is Associated with the Sustained Virological Response in HIV/Hepatitis C Virus-Coinfected Patients on Hepatitis C Virus Therapy.

Pineda-Tenor D, Jiménez-Sousa MA, Rallón N, Berenguer J, Soriano V, Aldámiz-Echevarria T, García-Álvarez M, Diez C, Fernández-Rodríguez A, Benito JM, Resino S.

AIDS Res Hum Retroviruses. 2016 Mar;32(3):226-31. doi: 10.1089/AID.2015.0223.

PMID:
26499461
18.

Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV response.

Bani-Sadr F, Krastinova E, Fromentin D, Piroth L, Rosenthal E, Quertainmont Y, Perronne C, Cacoub P, Pol S, Carrat F; ANRS CO 07-Ribavic Study team..

J Viral Hepat. 2012 Jun;19(6):431-5. doi: 10.1111/j.1365-2893.2011.01570.x.

PMID:
22571905
19.

Decreased anti-hepatitis C virus titer and associated factors in chronic hepatitis C patients after sustained virological response: a prospective study.

Kee KM, Wang JH, Hung CH, Chen CH, Lee CM, Chang KC, Tseng PL, Yen YH, Lin CY, Lu SN.

J Gastroenterol Hepatol. 2012 Jun;27(6):1106-11. doi: 10.1111/j.1440-1746.2011.06946.x.

PMID:
22004331
20.

CXCL9, CXCL10 and CXCL11 polymorphisms are associated with sustained virologic response in HIV/HCV-coinfected patients.

Pineda-Tenor D, Berenguer J, Jiménez-Sousa MA, Guzmán-Fulgencio M, Aldámiz-Echevarria T, Carrero A, García-Álvarez M, Diez C, Tejerina F, Briz V, Resino S.

J Clin Virol. 2014 Nov;61(3):423-9. doi: 10.1016/j.jcv.2014.08.020.

PMID:
25218243
Items per page

Supplemental Content

Support Center